OVER DEZE AFLEVERING
What happens when IVIG becomes so difficult to tolerate that a patient is ready to stop treatment?
IgNS Chief Clinical Officer Amy Clark joins host Rachel Coletta to discuss IVIG tolerability, individualized infusion care, patient advocacy, and why “common” does not necessarily mean “acceptable.”
Amy shares the story of a patient who spent years experiencing severe symptoms following his IVIG treatments and had reached the point of wanting to discontinue therapy. What happened when the care team took a closer look at his experience illustrates the importance of listening, individualizing treatment, considering IVIG and SCIG options, and involving patients in decisions about their care.
🎧 IN THIS EPISODE
✓ Recognizing when IVIG tolerability problems require intervention
✓ Why infusion rate and individualized administration matter
✓ Listening before accepting poor tolerability as “normal”
✓ Considering IVIG and SCIG options as patient needs change
✓ How patient experiences helped shape Ig therapy standards of practice
👤 ABOUT THE GUEST
Amy Clark has more than 30 years of nursing experience, including two decades in specialty home infusion. She serves as Chief Clinical Officer at IgNS and has contributed to the development and evolution of Ig therapy standards, professional education, and certification.
🔗 EXPLORE IgNS
🎙️ ABOUT NEXT QUESTION WITH IgNS
Next Question with IgNS brings together healthcare professionals, patients, researchers, and industry leaders to explore the questions and stories shaping Ig therapy, biologics, and patient care.
#IVIG #IgTherapy #SCIG #InfusionNursing #IgNS
